Basis: Unrounded diluted TTM EPS / FMP quote price × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The earnings yield is N/A as of 2026-10-06T20:33:14.790Z.
Calculation as of: 2026-10-06T20:33:14.790Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: b7fd3b5d8e417d78924f6cd313032c2aac5600bd184120b35a4860f29c1b1599
EARNINGS YIELD
N/A
Market Cap
$69.61M
Earnings Yield
N/A
TTM Avg
4.28%
3Y Avg
4.21%
5Y Avg
1.79%
Market Cap
$72.32M
Earnings Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$68.90M
Earnings Yield
9.24%
TTM Avg
9.77%
3Y Avg
14.46%
5Y Avg
14.46%
Market Cap
$68.10M
Earnings Yield
130.83%
TTM Avg
107.81%
3Y Avg
107.81%
5Y Avg
107.81%
| NAME | MARKET CAP | EARNINGS YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Tiziana Life Sciences Ltd (TLSA) | $70.63M | N/A | N/A | N/A | N/A |
| Gain Therapeutics, Inc. (GANX)vs › | $71.23M | N/A | N/A | N/A | N/A |
| Champions Oncology, Inc. (CSBR)vs › | $69.61M | N/A | 4.28% | 4.21% | 1.79% |
| Verrica Pharmaceuticals Inc. (VRCA)vs › | $72.32M | N/A | N/A | N/A | N/A |
| Spero Therapeutics, Inc. (SPRO)vs › | $68.90M | 9.24% | 9.77% | 14.46% | 14.46% |
| MindWalk Holdings Corp. (HYFT)vs › | $72.83M | N/A | N/A | N/A | N/A |
| Fortress Biotech, Inc. (FBIO)vs › | $68.10M | 130.83% | 107.81% | 107.81% | 107.81% |
| Hyperfine, Inc. (HYPR)vs › | $73.27M | N/A | N/A | N/A | N/A |
| iBio, Inc. (IBIO)vs › | $67.52M | N/A | 1.65% | 1.65% | 1.65% |
| Pulmonx Corporation (LUNG)vs › | $75.18M | N/A | N/A | N/A | N/A |
Earnings Yield
N/A
EPS ÷ Price
P/E Ratio
N/A
Price ÷ EPS
Formula: Earnings Yield = (EPS / Price) × 100
Earnings Yield is simply the inverse of P/E. A P/E of 20 equals a 5% earnings yield.
How earnings yield is used:
Earnings Yield = EPS (TTM) / Share Price
Earnings yield is the inverse of the PE ratio, expressing trailing earnings as a percentage of price. Higher is cheaper.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
